|
|
|
|
-
-
1. °æÇÇ¿ë BCG ¹é½ÅÀÇ ¿¹¹æÈ¿°ú´Â °ËÁõµÇ¾î ÀÖ³ª¿ä?
-
°æÇÇ¿ë BCG ¹é½ÅÀº BCG ¹é½Å Á¢Á¾ÀÇ ±¹¼Ò ÀÌ»ó¹ÝÀÀÀ» °æ°¨½Ã۰í
Á¢Á¾ ÈÄ Åõº£¸£Ä𸰠¹ÝÀÀ(°áÇÙ±Õ¿¡ ´ëÇÑ ¹ÝÀÀ)ÀÇ ¾ç¼ºÀüȯÀ²ÀÌ Çdz»Á¢Á¾°ú µ¿µîÇÏ´Ù´Â
µÎ °¡Áö ¿ì¼ö¼ºÀÌ È®ÀÎµÇ¾î °³¹ßµÈ ¹é½ÅÀÌ¿¡¿ä1.
ÀÚ¼¼È÷º¸±â
°æÇÇ¿ë BCG ¹é½ÅÀ» °³¹ßÇÑ ÀϺ»Àº 1967³âºÎÅÍ Çdz»Á¢Á¾¿¡¼ °æÇÇÁ¢Á¾À¸·Î Àü¸é ÀüȯÇß°í2,
Çѱ¹Àº 1993³â ½Ä¾àó¿¡¼ ¹é½ÅÀÇ À¯È¿¼ºÀ» ÀÎÁ¤¹Þ¾Æ Á¤½ÄÇã°¡¸¦ ¹Þ¾Ò¾î¿ä3.
°Ô´Ù°¡ ÇöÀç±îÁö ±¹³»¿¡ ¾à 700¸¸ ¸í ºÐ ÀÌ»óÀÌ °ø±Þ4µÇ¾î Á¢Á¾µÉ ¸¸Å, dzºÎÇÑ ÀÓ»ó°æÇèÀ» º¸À¯Çϰí ÀÖ´ä´Ï´Ù.
ÀÌ·¯ÇÑ °æÇÇ¿ë BCG ¹é½ÅÀÇ À¯È¿¼ºÀº ±¹³»¡¤¿Ü ¿©·¯ ÀÓ»óÀ» ÅëÇØ È®ÀεǾî ÀÖ±¸¿ä5-12.
°æÇÇ¿ë BCG ¹é½ÅÀ¸·Î 100% Á¢Á¾Çϰí ÀÖ´Â ÀϺ»°ú,
°æÇÇ¿ë BCG ¹é½Å Á¢Á¾·üÀÌ Àý¹Ý ÀÌ»óÀ» ³Ñ´Â Çѱ¹¿¡¼
¼Ò¾Æ °áÇÙȯÀÚ¼ö(0¼¼~14¼¼)°¡ ¸Å³â ²ÙÁØÈ÷ °¨¼ÒµÇ°í ÀÖ´Â Åë°è13.14´Â,
°æÇÇ¿ë BCG ¹é½ÅÀÇ ¿¹¹æÈ¿°ú¸¦ º¸¿©ÁÖ´Â ´ÜÀûÀÎ ¿¹Áö¿ä.
[ÀϺ»¿¡¼ 1967³â °æÇÇ¿ë BCG ¹é½Å µµÀÔÈÄ ½ÇÁ¦ ½Å°áÇ٠ȯÀÚ °¨¼ÒÀ²13]

- - ÀϺ»Àº 1967³â Çdz»¿ë BCG ¹é½Å¿¡¼ °æÇÇ¿ë BCG ¹é½ÅÀ¸·Î 100% ÀüȯµÊ2.
- - 1967³â °æÇÇ¿ë BCG ¹é½Å µµÀÔ ÀÌÈÄ, ÀϺ»ÀÇ ¼Ò¾Æ°áÇÙȯÀÚ¼ö´Â ±Þ°ÝÇÏ°Ô °¨¼ÒÇÏ¿´À½13.
[ Çѱ¹ÀÇ 0-14¼¼ ¼Ò¾Æ ½Å°áÇ٠ȯÀÚ¼ö ]14

- - Çѱ¹¿¡¼ Çdz»¿ë BCG ¹é½ÅÀº 1954³â NIP¿¡ óÀ½ µµÀÔ15µÇ¾ú°í,°æÇÇ¿ë BCG ¹é½ÅÀº 1994³â ¹ß¸ÅµÇ¾úÀ½
½ÇÁ¦·Î 2006³â °æÇÇÁ¢Á¾(Tokyo 172±ÕÁÖ), Çdz»Á¢Á¾(Tokyo 172±ÕÁÖ, Danish 1331±ÕÁÖ)¿¡ µû¸¥
°¢°¢ÀÇ ¸é¿ª¹ÝÀÀÀ» ºñ±³¡¤Æò°¡ÇÑ ¹Ì±¹ °¨¿°º´ÇÐȸÀÇ ³í¹®¿¡ µû¸£¸é,
°æÇÇÁ¢Á¾ÀÌ °°Àº Tokyo 172±ÕÁÖ¸¦ »ç¿ëÇÑ Çdz»Á¢Á¾À̳ª
Danish ±ÕÁÖ¸¦ »ç¿ëÇÑ Çdz»Á¢Á¾¿¡ ºñÇØ Ȱ¹ßÇÑ ¸é¿ª¹ÝÀÀÀ» À¯µµÇÑ´Ù°í ¹ßÇ¥µÇ¾ú¾î¿ä5.
±× ¹Û¿¡ ±¹³»¿Ü¿¡¼ Á¶»çµÈ ¸¹Àº ¿¬±¸¸¦ ÅëÇØ¼µµ ¾ÈÀü¼º°ú À¯È¿¼ºÀÌ È®ÀÎµÈ ¹é½ÅÀ̶ø´Ï´Ù5-12.
- Ref 1.

- Ref 2.

- Ref 3. °æÇÇ¿ë BCG ǰ¸ñ Çã°¡Áõ.
- Ref 4. Çѱ¹¹é½Å BCG Vaccine Sales Data, 2015³â 12¿ù ±âÁØ.
- Ref 5. Davids V, Hanekom W. A, Mansoor N, et al. The Effect of Bacille Calmette-Gue¢¥rin Vaccine Strain and Route of Administration on Induced Immune Responses in Vaccinated Infants. The journal of infactious Diseases 2006 : 193:531-536.
- Ref 6. Hawkridge A, et al. Efficacy of percutaneous versus intradermal BCG in the prvention of tuberculosis in South African infants ranomised trial. BMJ(British Medical Journal) 2008;337:a2052.
- Ref 7. ±è¿ì¼º, ±èâÈÖ ¿Ü 2ÀÎ. BCG Á¢Á¾¹æ¹ý¿¡ µû¸¥ °áÇÙ ¹ÝÀÀ°Ë»ç ¾çÀü·üÀÇ ºñ±³. ¼Ò¾Æ°ú Á¦ 40±Ç Á¦ 4È£ 1997.
- Ref 8. ±è¿ÏÁÖ, À̼±È£ ¿Ü 3ÀÎ. °³¿ø°¡ÀÇ ½Å»ý¾Æ BCG Á¢Á¾ ÈÄ Åõº£¸£Ä𸰠¹ÝÀÀ Æò°¡. ¼Ò¾Æ°¨¿° Á¦ 9±Ç Á¦2È£ 2002.
- Ref 9. ³ëÇý¿Á, ÀÌ¿ì±æ. °Ç°ÇÑ ¿µ¾Æ¿¡¼ °æÇÇ´ÙÀÚ¹ý BCG Á¢Á¾ÈÄ 2TU Åõº£¸£Ä𸰠°Ë»çÀÇ ¹ÝÀÀ¼º. ¼Ò¾Æ°¨¿° Á¦6±Ç Á¦1È£ 1999.
- Ref 10. ±èº¸¼±, Ȳ¹ÎÈ£, ±èâÈÖ ¿Ü2ÀÎ. °æÇÇ¿ë BCG ¹é½ÅÀÇ PPD 1T U, 2T U ¹× 5T U °áÇÙ ÇǺιÝÀÀ °Ë»ç¿¡ ´ëÇÑ ¿µÇâ. ¼Ò¾Æ°¨¿° Á¦8±Ç Á¦2È£ 2001.
- Ref 11. ÀÌÁø¼ö, ¼Õ¿µ¸ð. °æÇÇ¿ë °ÇÁ¶ B.C.G. ¹é½Å(Tokyo 172ÁÖ) Á¢Á¾ ÈÄ ±¹¼Ò ¹ÝÀÀ°ú Åõº£¸£Ä𸰠¾çÀüÀ²¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°¨¿° Á¦7±Ç Á¦2È£ 2000.
- Ref 12. ¿À¸íÈ£, ±è±âÇõ, ½ÉÀç°Ç. ½Å»ý¾Æ¿¡¼ °æÇÇ¿ë BCG Á¢Á¾ÈÄ ÇǺΠº¯È¿Í °áÇÙ ¹ÝÀÀ ¾ç¼º·ü ¹× ÇÕº´Áõ¿¡ ´ëÇÑ °íÂû. ¼Ò¾Æ°ú Á¦40±Ç Á¦8È£ 1997.
- Ref 13. JATA(ÀϺ»±¹¸³°áÇÙ¿¹¹æÇùȸ). ½Åµî·Ï ¼Ò¾Æ°áÇÙȯÀÚ¼ö ¹× ƯÁ¤Æó¿Ü°áÇÙ. °áÇÙÀÇ Åë°è 2016.
- Ref 14. º¸°Çº¹ÁöºÎ. Åë°è¿¬º¸(1994~2000). Åë°èû °áÇÙ ½Å°í ½ÅȯÀÚ ÇöȲ(2001~2015).
- Ref 15. ÀÌÁ¾±¸, ÃÖ¿ø¼®. ¿ì¸®³ª¶óÀÇ ¹é½Å Á¤Ã¥. °¨¿°°ú ÈÇпä¹ý Á¦ 40±Ç Á¦ 1È£, 2008.
-
-
2. °æÇÇ¿ë BCG¹é½Åµµ Çdz» BCG ó·³ ÀÏÁ¤·®ÀÇ ±ÕÁÖ¸¦ ÁÖÀÔÇÏ´Â ¹æ½ÄÀΰ¡¿ä?
-
°æÇǹýÀº Çdz»¹ý°ú´Â ÀüÇô ´Ù¸¥ ÀÛ¿ë ±âÀüÀ» Áö´Ñ Á¢Á¾ ¹æ¹ýÀ̶ø´Ï´Ù.
Á¢Á¾ ½Ã ÇÇÇÏÁ¢Á¾À¸·ÎÀÇ À§ÇèÀ» ÁÙÀ̰í, º¸´Ù ¾ÈÀüÇÏ°í Æí¸®ÇÑ Á¢Á¾À» À§ÇØ ÀϺ»¿¡¼ °³¹ßµÈ Á¢Á¾ ¹æ½ÄÀä1
ÀÚ¼¼È÷º¸±â
°æÇǹýÀ̶õ, ÇǺο¡ 9°³ÀÇ ¹Ì¼¼ÇÑ °üħÀ¸·Î »óó¸¦ ³½ ÈÄ, ¾à¾×ÀÌ »óó »çÀÌ·Î ÀÚ¿¬½º·´°Ô ½º¸çµé°Ô ÇÏ´Â Á¢Á¾¹ýÀ¸·Î, ÇǺÎÇ¥¸éÀÇ °¢ÁúÃþ¿¡¼ ÁøÇÇÃþ¿¡ À̸£±â±îÁö ÆÛÁ®ÀÖ´Â ÁöÁú, ¸ð³¶, ÇÇÁö¼±, ¶¡»ù µî¿¡ ÀÇÇØ ¾à¾×ÀÌ ºü¸£°Ô Èí¼öµÈ ÈÄ, Ç÷¾×ÀÇ È帧À» ÅëÇØ Àü½Å¿¡ ¿î¹ÝµÇ°Ô²û ÇÏ´Â Á¢Á¾ ¹æ½ÄÀ» ¸»ÇÑ´ä´Ï´Ù2.
µû¶ó¼, °æÇÇ¿ë BCG ¹é½ÅÀº ÇǺΠÀüü¸¦ ÅëÇØ ¾à¾×ÀÌ ºü¸£°Ô Èí¼öµÉ ¼ö ÀÖµµ·Ï
±Õ·®°ú ´ÜÀ§°¡ ÀüÇô ´Ù¸£°Ô ¼³Á¤(ml´ç ÀϺ» Çdz»¿ë BCG ¹é½Å ³óµµÀÇ ¾à 100¹è ÀÌ»ó)µÇ¾î ÀÖ¾î¿ä.3
ÀÌ·¸µí Ư¼öÇÏ°Ô °í¾ÈµÈ ¾à¾×°ú °üħÀ» »ç¿ëÇØ Á¢Á¾ÇÒ °æ¿ì,
Çdz»ÁÖ»ç·Î Á¢Á¾ÇßÀ»¶§¿Í µ¿ÀÏÇÑ Åõº£¸£Ä𸰹ÝÀÀ(°áÇÙ±Õ¿¡ ´ëÇÑ ¹ÝÀÀ) ¾çÀüÀ²À»
¾òÀ» ¼ö ÀÖ´Ù´Â »ç½ÇÀÌ ÀÓ»ó½ÃÇèÀ» ÅëÇØ Áõ¸íµÇ¾ú°í3, ±¹³»¿ÜÀÇ ¸¹Àº ¿¬±¸¸¦ ÅëÇØ ¹é½ÅÀÇ À¯È¿¼º°ú ¾ÈÀü¼º ¶ÇÇÑ È®ÀεǾî ÀÖ´ä´Ï´Ù4-11.
- Ref 1.

- Ref 2.À̹ÎÈ¡¤±¸¿µ¼ø, ½Å¾àÁ¦ÇÐ Á¦ 3ÆÇ p466, 2004.
- Ref 3.

- Ref 4.Davids V, Hanekom W. A, Mansoor N, et al. The Effect of Bacille Calmette-Gue¢¥rin Vaccine Strain and Route of Administration on Induced Immune Responses in Vaccinated Infants. The journal of infactious Diseases 2006 : 193:531-536.
- Ref 5.Hawkridge A, et al. Efficacy of percutaneous versus intradermal BCG in the prvention of tuberculosis in South African infants ranomised trial. BMJ(British Medical Journal) 2008;337:a2052.
- Ref 6.±è¿ì¼º, ±èâÈÖ ¿Ü 2ÀÎ. BCG Á¢Á¾¹æ¹ý¿¡ µû¸¥ °áÇÙ ¹ÝÀÀ°Ë»ç ¾çÀü·üÀÇ ºñ±³. ¼Ò¾Æ°ú Á¦ 40±Ç Á¦ 4È£ 1997.
- Ref 7.±è¿ÏÁÖ, À̼±È£ ¿Ü 3ÀÎ. °³¿ø°¡ÀÇ ½Å»ý¾Æ BCG Á¢Á¾ ÈÄ Åõº£¸£Ä𸰠¹ÝÀÀ Æò°¡. ¼Ò¾Æ°¨¿° Á¦ 9±Ç Á¦2È£ 2002.
- Ref 8.³ëÇý¿Á, ÀÌ¿ì±æ. °Ç°ÇÑ ¿µ¾Æ¿¡¼ °æÇÇ´ÙÀÚ¹ý BCG Á¢Á¾ÈÄ 2TU Åõº£¸£Ä𸰠°Ë»çÀÇ ¹ÝÀÀ¼º. ¼Ò¾Æ°¨¿° Á¦6±Ç Á¦1È£ 1999.
- Ref 9.±èº¸¼±, Ȳ¹ÎÈ£, ±èâÈÖ ¿Ü2ÀÎ. °æÇÇ¿ë BCG ¹é½ÅÀÇ PPD 1T U, 2T U ¹× 5T U °áÇÙ ÇǺιÝÀÀ °Ë»ç¿¡ ´ëÇÑ ¿µÇâ. ¼Ò¾Æ°¨¿° Á¦8±Ç Á¦2È£ 2001.
- Ref 10.ÀÌÁø¼ö, ¼Õ¿µ¸ð. °æÇÇ¿ë °ÇÁ¶ B.C.G. ¹é½Å(Tokyo 172ÁÖ) Á¢Á¾ ÈÄ ±¹¼Ò ¹ÝÀÀ°ú Åõº£¸£Ä𸰠¾çÀüÀ²¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°¨¿° Á¦7±Ç Á¦2È£ 2000.
- Ref 11.¿À¸íÈ£, ±è±âÇõ, ½ÉÀç°Ç. ½Å»ý¾Æ¿¡¼ °æÇÇ¿ë BCG Á¢Á¾ÈÄ ÇǺΠº¯È¿Í °áÇÙ ¹ÝÀÀ ¾ç¼º·ü ¹× ÇÕº´Áõ¿¡ ´ëÇÑ °íÂû. ¼Ò¾Æ°ú Á¦40±Ç Á¦8È£ 1997.
-
-
3. °æÇÇ¿ë BCG ¹é½Å Á¢Á¾Àº ±â¼úÀûÀ¸·Î ¾î·Á¿î°¡¿ä?
-
°æÇÇÁ¢Á¾Àº ±â¼úÀûÀ¸·Î º¹ÀâÇϰí Á¢Á¾ÀÚ¿¡ µû¶ó °³ÀÎÂ÷°¡ Å©´Ù°í °£È¤ ¾ð±ÞµÇÁö¸¸, ÀÌ´Â À߸ø ¾Ë·ÁÁø ³»¿ëÀÌ¿¡¿ä.
ÀÚ¼¼È÷º¸±â
[°æÇÇ¿ë BCG Á¢Á¾¹æ¹ý]
°æÇÇ¿ë BCG ¹é½ÅÀÇ Á¦Á¶±¹ÀÎ ÀϺ»Àº ÇöÀç±îÁö 50³â°£ 100% °æÇÇ¿ë BCG ¹é½ÅÀ» Á¢Á¾Çϰí Àִµ¥¿ä,
Á¢Á¾ ±¹¼Ò¹ÝÀÀÀÇ °æ°¨°ú Åõº£¸£Ä𸰠¹ÝÀÀ(°áÇÙ±Õ¿¡ ´ëÇÑ ¹ÝÀÀ)ÀÇ ¾ç¼ºÀüȯÀ²ÀÌ
Çdz»Á¢Á¾°ú µ¿µîÇÏ´Ù´Â Á¡ À̿ܿ¡µµ Á¢Á¾ ±â¼úÀÌ º¸´Ù ½±´Ù´Â Á¡ ¿ª½Ã °æÇǹýÀÇ ÀåÁ¡À¸·Î ²ÅÈ÷°í ÀÖ´ä´Ï´Ù1.
°æÇǹýÀº Á¦´ë·Î Á¢Á¾ °½ÀÀ» ¹Þ°Ô µÇ¸é, ¾î·Á¿î ±â¼ú ¾øÀ̵µ ¿Ã¹Ù¸¥ Á¢Á¾ÀÌ °¡´ÉÇØ¿ä1.
- Ref 1.

-
-
4. °æÇÇ¿ë BCG ¹é½ÅÀº ºÎÀÛ¿ë¿¡ ´ëÇÑ º¸»óÀ» ¹ÞÀ» ¼ö ÀÖ³ª¿ä?
-
°æÇÇ¿ë BCG ¹é½ÅÀº ÇöÀç ±¹°¡Çʼö¿¹¹æÁ¢Á¾(NIP)¿¡ ÇØ´çµÇÁö ¾Ê±â ¶§¹®¿¡,
ÀÌ»ó¹ÝÀÀÀÌ ¹ß»ýÇßÀ» °æ¿ì ¿¹¹æÁ¢Á¾ÇÇÇØ ±¹°¡º¸»ó ÀýÂ÷¸¦ ÅëÇØ º¸»ó¹ÞÀ» ¼ö ¾ø¾î¿ä.
ÇÏÁö¸¸, ¼öÀÔ¿øÀÎ ÀúÈñ ¢ßÇѱ¹¹é½Å»ó»ç¿¡¼´Â ÀÚ»ç ±âÁØ¿¡ ÀǰÅÇÏ¿©
ÀÌ»ó¹ÝÀÀ °ü·Ã ÀÚü Áö¿øÀ» Á¦Ç° Ãâ½Ã ÀÌ·¡ Áö¼ÓÀûÀ¸·Î ½Ç½ÃÇØ¿À°í ÀÖ¾ú´ä´Ï´Ù.
ÀÚ¼¼È÷º¸±â
2017³â 1¿ùºÎÅÍ ¾à»ç¹ý Á¦ 86Á¶¿¡ µû¶ó ½ÄǰÀǾàǰ¾ÈÀüó »êÇÏ Çѱ¹ÀǾàǰ¾ÈÀü°ü¸®¿øÀÇ
ÀǾàǰ ºÎÀÛ¿ë ÇÇÇØ ±¸Á¦Á¦µµ¸¦ ÅëÇØ, '2014³â 12¿ù 19ÀÏ ÀÌÈÄ ¹ß»ýÇÑ' °æÇÇ¿ë BCG ¹é½Å °ü·Ã ÀÌ»ó¹ÝÀÀ °ÇµéÀÇ ÇÇÇØº¸»óÀ»
±¹°¡¿¡ ½ÅûÇÒ ¼ö ÀÖ´Ù´Â ±â»çµµ ¾ó¸¶ Àü¿¡ º¸µµµÇ¾úÁö¿ä.
(±â»ç ¿ø¹® : http://www.newspim.com/news/view/20160906000104)
Áï, 2017³â 1¿ùºÎÅÍ Á¢Á¾ÀÏ ±âÁØÀ¸·Î 2³â Àü¿¡ Á¢Á¾ÇÏ¿© ºÎÀÛ¿ëÀÌ »ý±ä °æ¿ì,
ÀǾàǰ ºÎÀÛ¿ë ÇÇÇØ ±¸Á¦Á¦µµ¸¦ ÅëÇØ¼ º¸»ó ¹ÞÀ» ¼ö ÀÖ¾î¿ä.
(»ç¸Á, Àå¾Ö°¡ ¹ß»ýÇÏ¿´°Å³ª Áúº´ÀÌ ¹ß»ýÇÏ¿© ÀÔ¿øÄ¡·á¸¦ ¹ÞÀ¸½Å ºÐµé Áß ±¹¹Î°Ç°º¸Çè¹ý ¶Ç´Â
ÀÇ·á±Þ¿©¹ý¿¡ µû¶ó º»Àκδã±Ý 30¸¸¿ø ÀÌ»óÀÏ °æ¿ì Àû¿ëµÊ.
´Ü, º´¿øÄ¡·á ¾øÀÌ È£ÀüµÇ¾ú°Å³ª Åë¿øÄ¡·á¸¸À¸·Î È£ÀüµÈ °æ¿ì Á¦¿ÜµÊ.)
±×·¯³ª ÀǾàǰ ºÎÀÛ¿ë ÇÇÇØ ±¸Á¦Á¦µµ º¸»óÀýÂ÷ Á¶°Ç¿¡ ºÎÇÕ µÇÁö ¾Ê´Â °æ¿ì, ÀÚ»ç ±âÁØ¿¡ µû¶ó Áö¿øÀÌ °¡´ÉÇϱ⵵ ÇØ¿ä.
ÀÚ»ç Áö¿ø ±âÁØÀº ¾Æ·¡¿Í °°´ä´Ï´Ù.
Áö¿ø¹üÀ§ |
¿¹¹æÁ¢Á¾ÇÇÇØ±¹°¡º¸»óÀýÂ÷°¡ º¸ÀåÇÏ´Â °Í°ú µ¿ÀϹüÀ§ ¹×
Àڻ簡 µ¿ÀÇÇÏ´Â ºÎ´ëºñ¿ë |
Áö¿øÈ½¼ö |
Ä¡·á°¡ ¿Ï·áµÇ´Â ½ÃÁ¡±îÁö Ƚ¼ö¿¡ »ó°ü¾øÀÌ Áö¿ø |
Áö¿ø½Åû ±âÁØ ±Ý¾× |
±¹¹Î°Ç°º¸Çè¹ý ¶Ç´Â ÀÇ·á±Þ¿©¹ý¿¡ Áø·á½ÇºñÁö¿ø (´Ü, ºñ±Þ¿©´Â ÀÚ»ç¿Í ÇùÀÇ ÈÄ Áö¿ø°¡´É) |
Áö±Þ±âÀÏ |
Á¢¼ö ÈÄ ÃÖ´ëÇÑ ½Å¼ÓÈ÷ ½ÉÀÇ, ÇÊ¿ä ¼·ù ¼ö·É ÈÄ ¿µ¾÷ÀÏ 5ÀÏ À̳» Áö±Þ |
Çʿ伷ù |
Áø´Ü¼(¼Ò°ß¼), ÀÔ¿ø ¹× ¼ö¼ú½Ã(ÀÔ·Åð¿øÈ®Àμ), Áø·áºñ¿µ¼öÁõ, Áֹεî·Ïµîº»(°¡Á·°ü°èÁõ¸í¼), ÅëÀå»çº», °³ÀÎÁ¤º¸µ¿ÀǼ |
ÀÌ»ó¹ÝÀÀ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ »ó´ãÀ» ¿øÇϽô ºÐÀº ¢ß Çѱ¹¹é½Å(Tel :02-443-1961)·Î ¿¬¶ôÁֽøé Ä£ÀýÇÏ°Ô ¾È³»Çص帮µµ·Ï ÇϰڽÀ´Ï´Ù.
-
-
5. °æÇÇ¿ë BCG ¹é½ÅÀ¸·Î Á¢Á¾Çϸé ÈäÅͰ¡ ¾È »ý±â³ª¿ä?
-
±×·¸Áö ¾Ê½À´Ï´Ù,
BCG ¹é½ÅÀÇ Á¢Á¾ ÈäÅÍ(¹ÝÈç)´Â ¾ÆÀÌÀÇ »ì¼º µî ´Ù¾çÇÑ ¿äÀο¡ µû¶ó ³²À» °¡´É¼ºÀÌ ÀÖ°í
ÈäÅÍ(¹ÝÈç)ÀÇ »óųª °³¼ö ¿ª½Ã Â÷À̰¡ ÀÖÀ» ¼ö ÀÖ¾î¿ä1-5.
ÀÚ¼¼È÷º¸±â
½ÇÁ¦·Î °æÇÇ¿ë BCG ¹é½ÅÀº 9°³ÀÇ ¹Ì¼¼ÇÑ Ä§ÀÌ ÀÏÁ¤ °£°ÝÀ¸·Î ¹èÄ¡µÇ¾î,
Á¢Á¾ ±¹¼Ò ºÎÀ§¿¡ °¡ÇØÁö´Â ÈûÀ» ºÐ»ê½Ãų ¼ö ÀÖµµ·Ï °í¾ÈµÇ¾ú´ä´Ï´Ù.
Áï, ¾ÆÀÌ »ì¼º¿¡ µû¶ó Â÷ÀÌ´Â ÀÖ°ÚÁö¸¸ ±âº»ÀûÀ¸·Î ±¹¼Ò ¹ÝÀÀÀÌ Àûµµ·Ï ¼³°èµÈ °ÍÀ¸·Î6
°æÇÇ¿ë BCG ¹é½ÅÀ» Á¢Á¾ÇÑ ÈÄ ¸î ³âÀÌ Áö³ª¸é ÈäÅÍ(¹ÝÈç)°¡ Èñ¹ÌÇÑ ÀÚ±¹À¸·Î ³²°Ô µË´Ï´Ù.
- Ref 1.±èÁ¾Çö ¿Ü 6ÀÎ. The Number of Scars in Percutaneous Tokyo Strain BCG is not a Reliable Parameter
to Appraise the BCG Immune Reactions. ¼Ò¾Æ°¨¿°º´ÇÐȸ ÃÊ·ÏÁý 2012³â.
- Ref 2.ÀÌÁø¼ö, ¼Õ¿µ¸ð. °æÇÇ¿ë °ÇÁ¶B.C.G.¹é½Å (Tokyo 172ÁÖ) Á¢Á¾ ÈÄ ±¹¼Ò ¹ÝÀÀ°ú Åõº£¸£Ä𸰠¾çÀüÀ²¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°¨¿° Á¦7±Ç Á¦2È£ p201-210, 2000³â.
- Ref 3.´ëÇѼҾưúÇÐȸ. BCG(Bacille Calmette-Guerin) ¹é½Å. ¿¹¹æÁ¢Á¾Áöħ¼ Á¦8ÆÇ. p65, 2015³â.
- Ref 4.Áúº´°ü¸®º»ºÎ. ¿¹¹æÁ¢Á¾ ´ë»ó °¨¿°º´ÀÇ ¿ªÇаú °ü¸®. ¿¹¹æÁ¢Á¾ ½Ç½Ã ±âÁØ ¹× ¹æ¹ý Á¦ 4ÆÇ ¼öÁ¤ÆÇ p75, 2013³â.
- Ref 5.

- Ref 6.

-
-
6. BCG ¹é½Å Á¢Á¾ ÈÄ Á¢Á¾ÈçÀÌ º¸ÀÌÁö ¾ÊÀ¸¸é, ÀçÁ¢Á¾ÇØ¾ß Çϳª¿ä?
-
Á¢Á¾ ÈÄ ¹ß»ýÇÏ´Â ÈäÅÍ(¹ÝÈç)´Â ¾ÆÀÌÀÇ »ì¼º µî¿¡ ¿µÇâÀ» ¹Þ´Â´ä´Ï´Ù.
±¹³»¡¤¿Ü¿¡ ¹ßÇ¥µÈ Àڷᳪ ³í¹®¿¡¼µµ Á¢Á¾ ÈÄ ¹ß»ýÇÑ ÈäÅÍ(¹ÝÈç)ÀÇ °³¼ö´Â °³Àθ¶´Ù Â÷À̰¡ ÀÖ¾ú°í,
ÈäÅÍ(¹ÝÈç)°¡ ³²Áö ¾Ê´Â °æ¿ìµµ ÀÖ¾ú¾î¿ä1-5.
ÀÚ¼¼È÷º¸±â
ÇÏÁö¸¸, ÈäÅÍ(¹ÝÈç)ÀÇ °³¼ö°¡ °áÇÙ¿¡ ´ëÇÑ ¸é¿ª·Â Çü¼ºÀ» ÆÇ´ÜÇÏ´Â ±âÁØÀÌ ¾Æ´Ï¶ó´Â »ç½ÇÀÌ ÀÌ¹Ì ¹ßÇ¥µÇ¾ú°í1-5,
±¹³» ¼Ò¾Æ°úÇÐȸÀÇ BCG Á¢Á¾Áöħ¿¡¼µµ,
¡®Á¢Á¾·ÂÀÌ ÀÖ´Ù¸é, ÈäÅÍ(¹ÝÈç)°¡ ¾ø´Ù ÇØµµ ÀçÁ¢Á¾À» ±ÇÀåÇÏÁö´Â ¾Ê´Â´Ù¡¯ ¶ó°í ±âÀçµÇ¾î ÀÖ´ä´Ï´Ù3.
- Ref 1.±èÁ¾Çö ¿Ü 6ÀÎ. The Number of Scars in Percutaneous Tokyo Strain BCG is not a eliable Parameter to Appraise the BCG Immune Reactions. ¼Ò¾Æ°¨¿°º´ÇÐȸ ÃÊ·ÏÁý 2012³â.
- Ref 2.ÀÌÁø¼ö, ¼Õ¿µ¸ð. °æÇÇ¿ë °ÇÁ¶B.C.G.¹é½Å (Tokyo 172ÁÖ) Á¢Á¾ ÈÄ ±¹¼Ò ¹ÝÀÀ°ú Åõº£¸£Ä𸰠¾çÀüÀ²¿¡ °üÇÑ ¿¬±¸. ¼Ò¾Æ°¨¿° Á¦7±Ç Á¦2È£ p201-210, 2000³â.
- Ref 3.´ëÇѼҾưúÇÐȸ. BCG(Bacille Calmette-Guerin) ¹é½Å. ¿¹¹æÁ¢Á¾Áöħ¼ Á¦8ÆÇ. p65, 2015³â.
- Ref 4.Áúº´°ü¸®º»ºÎ. ¿¹¹æÁ¢Á¾ ´ë»ó °¨¿°º´ÀÇ ¿ªÇаú °ü¸®. ¿¹¹æÁ¢Á¾ ½Ç½Ã ±âÁØ ¹× ¹æ¹ý Á¦ 4ÆÇ ¼öÁ¤ÆÇ p75, 2013³â.
- Ref 5.

-
-
7. WHO¿¡¼´Â Çdz»¿ë BCG ¹é½ÅÀ» ±ÇÀåÇÑ´Ù´øµ¥ ÀÌÀ¯°¡ ÀÖ³ª¿ä?
-
°ú°Å WHO´Â Çdz»¿ë BCG ¹é½ÅÀ» ±ÇÀåÇÑ´Ù(recommends)°í ÇßÀ¸³ª, 2018³â 2¿ù ¹ßÇàµÈ WHOÀÇ Weekly epidemiological recordÀÇ BCG Vaccines WHO Position paper¸¦ ÅëÇØ ¡°±ÇÀåÇÑ´Ù(recommends)¡±´Â ¹®±¸°¡ »èÁ¦µÇ¾ú°í ´ÙõÀÚħÀ» ÀÌ¿ëÇÑ °æÇÇ Åõ¿©¹ý »ç¿ëÀÌ Çã¿ëµÈ Á¦Ç°ÀÌ Á¸ÀçÇÔÀ» È®ÀÎÇÒ ¼ö ÀÖ¾î¿ä ÀÌ¿ÍÇÔ²² WHO´Â ´Ù¾çÇÑ BCG ¹é½Å Á¦Ç°µéÀÇ »ç¿ë¿¡ ÀÖ¾î ¼±È£µÇ´Â Á¦Ç°Àº ¾øÀ¸¸ç À̴ ƯÁ¤ ¿¬·ÉÀ̳ª À§Çè±×·ì¿¡¼µµ ¸¶Âù°¡ÁöÀÓÀ» Ç¥¸íÇßÁö¿ä1-2.
Âü°í·Î ¼±Áø±¹¿¡¼´Â Çdz»¿ë BCG ¹é½ÅÀÌ ¾Æ´Ñ °æÇÇ¿ë BCG ¹é½ÅÀ» °³¹ßÇß¾î¿ä.
Áï ¹Ì±¹, ¿µ±¹, ÇÁ¶û½º, ÀϺ»¿¡¼ °æÇÇ¿ë BCG ¹é½ÅÀ» °¢°¢ °³¹ßÇßÁö¸¸3-6
ÇöÀç ¼±Áø±¹µé ´ëºÎºÐÀº »ó´ëÀûÀ¸·Î °áÇٹߺ´·üÀÌ ³·¾Æ¼,
BCG ¹é½Å Á¢Á¾À» ¿ì¸®³ª¶ó³ª ÀϺ»Ã³·³ ±¹°¡¿¹¹æÁ¢Á¾À¸·Î äÅÃÇϰí ÀÖÁö´Â ¾Ê´ä´Ï´Ù.
ÀÚ¼¼È÷º¸±â
°áÇÙÀº ÁÖ·Î °³¹ßµµ»ó±¹°¡¿¡¼ ¹ß»ýÇØ¿ä.
´ëºÎºÐÀº ¾Æ½Ã¾Æ(55%)¿Í ¾ÆÇÁ¸®Ä«(30%)¿¡¼ ¹ß»ýÇϰí ÀÖ°í,
±¹°¡º°·Î´Â Àεµ(200¸¸¸í), Áß±¹(130¸¸¸í), ³²¾ÆÇÁ¸®Ä«°øÈ±¹(49¸¸¸í), ³ªÀÌÁö¸®¾Æ(46¸¸¸í),
Àεµ³×½Ã¾Æ(43¸¸¸í) ¼øÀ¸·Î ¸¹´ä´Ï´Ù7.
WHO(¼¼°èº¸°Ç±â±¸)´Â UNICEF(À¯´Ï¼¼ÇÁ : UN»êÇÏ ¾Æµ¿±¸È£±â°ü)¸¦ ÅëÇØ, Çdz»¿ë BCG ¹é½ÅÀ» °ø±ÞÇϰí Àִµ¥¿ä8.
Çdz»¿ë BCG ¹é½ÅÀº ÇÑ ¹ÙÀ̾Ë(º´) ´ç ÃÖ´ë 20¸í±îÁö Á¢Á¾ÇÒ ¼ö ÀÖ´Â ´ÙÀÎ¿ë ¹é½ÅÀ¸·Î 1ÀÎ 1ȸ¿ë ¹é½ÅÀÎ °æÇÇ¿ë BCG ¹é½Å°ú´Â Â÷À̰¡ ÀÖ¾î¿ä.
±× µ¿¾È WHO°¡ Çdz»¿ë BCG¸¦ ±ÇÀåÇß´ø °ÍÀº, WHO°¡ ¹ü±¹°¡ÀûÀÎ ´ë±Ô¸ð °¨¿° ¿¹¹æÀ̶ó´Â ¸ñÀû¿¡ µû¶ó,
¹é½ÅÀÇ À¯È¿¼º ¹× ¾ÈÀü¼º, ¹é½Å ±¸¸Åºñ¿ë, ±×¸®°í Á¢Á¾±¹°¡µéÀÇ »óȲ µî
Á¾ÇÕÀûÀÎ ÆÇ´Ü¿¡ µû¸¥ °ÍÀ̶ó°í »ý°¢ÇÒ ¼ö ÀÖ¾î¿ä.
Âü°í·Î Çdz»¿ë BCG ¹é½ÅÀº 1928³â¿¡ °³¹ßµÈ Á¢Á¾¹ýÀ̰í9,
9°³ÀÇ °üħÀ» »ç¿ëÇÑ °æÇÇ¿ë BCG ¹é½ÅÀº 1964³â¿¡ ÀϺ»¿¡¼ °í¾ÈµÇ¾ú´Âµ¥¿ä9.
ÀϺ»ÀÇ °æ¿ì Çdz»¿ë BCG ¹é½Å ¿ª½Ã »ý»êÇϰí ÀÖÁö¸¸, ÀÚ±¹¹ÎÀº 100% °æÇÇ¿ë BCG ¹é½ÅÀ» Á¢Á¾Çϰí, »ý»êµÇ´Â Çdz»¿ë BCG ¹é½ÅÀº Àü·® ¼öÃâÇϰí ÀÖ¾î¿ä.
Âü°í·Î °æÇÇ¿ë BCG ¹é½ÅÀÇ 'Tokyo 172±ÕÁÖ'´Â 1965³â¿¡ WHO Reference Reagent(WHO ±¹Á¦Ç¥ÁØÇ°)·Î ¼±Á¤µÇ¾ú°í9
±¹Á¦ÀûÀÎ °øµ¿¿¬±¸¸¦ ÅëÇØ Æò°¡µÈµ¥´Ù, 2009³â 10¿ù WHO ECBS(¼¼°èº¸°Ç±â±¸ »ý¹°ÀǾàǰ Ç¥ÁØÈ Àü¹®°¡À§¿øÈ¸)¿¡ ÀÇÇØ äÅÃµÈ ±ÕÁÖÀ̱⵵ ÇØ¿ä10.
- Ref 1.World Health Organization, WEEKLY EPIDEMIOLOGICAL RECORD, NO. 4, 23 JANUARY 2004, 34p.
- Ref 2 .World Health Organization, WEEKLY EPIDEMIOLOGICAL RECORD, NO 8, 23 FEBRUARY 2018, 84p, 96p.
- Ref 3.Merck Homepage>Products>Vaccines&Prescribing Information, http://www.merck.com/product/
- Ref 4.Percutaneous BCG Vaccine BP, The Open University,
http://mcs.open.ac.uk/nlg/old_projects/pills/corpus/pil/data/Evans/Percutaneous_BDG_Vaccine_BP/Percutaneous_BDG_Vaccine_BP.html
- Ref 5.FRENCH INSTITUTE FOR PUBLIC HEALTH SURVEILLANCE, Low BCG Vaccination coverage after the end of compulsory vaccination in Ile-de-France(France), a region of high tuberculosis incidence, Otc. 2009.
- Ref 6.Japan BCG Laboratory Homepage>Our Products for Overseas Market, http://www.bcg.gr.jp/english/menu1.html
- Ref 7.´ëÇѼҾưúÇÐȸ, ¿¹¹æÁ¢Á¾Áöħ¼ Á¦ 8ÆÇ 54p, 2015.
- Ref 8.UNICEF, UNICEF information to countries on constrained BCG vaccine market, Available at : http://www.unicef.org/supply/index_82351.html
- Ref 9.

- Ref 10.NIBSC(The National Institute for Biological Standards and Control), BCG Standardisation, 2014.
-
-
8. °æÇÇ¿ë BCG ¹é½ÅÀº Á¢Á¾ ÈÄ ÀÌ»ó¹ÝÀÀÀÌ ¸¹ÀÌ ¹ß»ýÇϳª¿ä?
-
±×·¸Áö ¾Ê¾Æ¿ä.
ÀϺ» Á¤ºÎ¿¡¼´Â ±âÁ¸¿¡ »ç¿ëÇÏ´ø Çdz»¿ë BCG ¹é½ÅÀÇ ÀÌ»ó¹ÝÀÀ ¹®Á¦·Î
1967³â °æÇÇ¿ë BCG ¹é½ÅÀ¸·Î ÀüȯÇÏ¿©
ÇöÀç±îÁö °æÇÇ¿ë BCG ¹é½Å¸¸À» 100% »ç¿ëÇϰí ÀÖ¾î¿ä1.
ÀÚ¼¼È÷º¸±â
°æÇÇ¿ë BCG ¹é½ÅÀº ±¹¼Ò ¹ÝÀÀÀ» Æ÷ÇÔÇÑ ÀÌ»ó¹ÝÀÀ ¹ßÇöÀ²ÀÌ Çdz»¿ë BCG ¹é½Å¿¡ ºñÇØ
»ó´ëÀûÀ¸·Î Àû´Ù°í ¾Ë·ÁÁ® ÀÖ¾î¿ä2.
±¹¡¤³»¿ÜÀÇ ¹®ÇåÀ» ÅëÇØ¼µµ °æÇÇ¿ë BCG ¹é½ÅÀÌ Çdz»¿ë BCG ¹é½Åº¸´Ù ºÎÀÛ¿ëÀÌ Àû´Ù´Â Á¡ÀÌ º¸°íµÇ¾ú°í3.4
½ÇÁ¦·Î °æÇÇÁ¢Á¾À¸·Î Àϰý ÀüÈ¯ÇØ¼ 50³â °¡±îÀÌ °æÇÇ¿ë BCG ¹é½Å¸¸ Á¢Á¾ ÁßÀÎ ÀϺ»¿¡¼µµ
³ôÀº ¹æ¾îÈ¿°ú¿Í ³·Àº ÀÌ»ó¹ÝÀÀ ¹ßÇöÀ²À» º¸À̰í ÀÖÁö¿ä2.5.
ÀÌ»ó¹ÝÀÀÀÌ »ó´ëÀûÀ¸·Î ³·Áö¸¸,
¢ßÇѱ¹¹é½Å¿¡¼´Â °æÇÇ¿ë BCG ¹é½ÅÀÇ Ãâ½Ã ÀÌ·¡·Î ÀÌ»ó¹ÝÀÀ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú
ÀÚ»ç ±ÔÁ¤¿¡ ÀǰÅÇÑ º¸»ó Á¤Ã¥ ¶ÇÇÑ ²ÙÁØÈ÷ ½Ç½ÃÇØ¿À°í ÀÖ´ä´Ï´Ù.
(Çѱ¹¹é½Å º¸»ó Á¤Ã¥ : FAQ 4¹ø ÂüÁ¶)
- Ref 1.

- Ref 2.Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th ed. P789-811, Philadelphia, Elsevier Inc., 2013.
- Ref 3.±èÁ¾Çö, °¡Å縯´ëÇб³ Àǰú´ëÇÐ, BCG ¹é½ÅÀÇ À¯¿ë¼º Æò°¡-BCG ¹é½Å ¸²ÇÁÀý¿° ¹ß»ý¾Æ¿¡ ´ëÇÑ ¸é¿ª»óÅ Á¶»ç, 10 Feb. 2010.
- Ref 4.WHO(World Health Organization), Weekly Epidemiological Record, 382p, 9 Dec. 1988.
- Ref 5.JATA(Japan Anti-tuberculosis Association) ½Åµî·Ï ¼Ò¾Æ°áÇÙȯÀÚ¼ö ¹× ƯÁ¤Æó¿Ü°áÇÙ, °áÇÙÀÇ Åë°è 2016.
-
-
9. °æÇÇ¿ë BCG ¹é½ÅÀº ¹æ»ç´É °Ë»ç¸¦ ÁøÇàÇϳª¿ä?
-
°æÇÇ¿ë BCG ¹é½Å¿¡´Â ¹æ»ç¼º ¹°ÁúÀÌ Æ÷ÇԵǾîÀÖÁö ¾Ê½À´Ï´Ù1
ÀÚ¼¼È÷º¸±â
±×·³¿¡µµ ºÒ±¸Çϰí 2011³â ÀÌÈÄ ¼öÀÔ¿øÀÎ ÀúÈñ ¢ßÇѱ¹¹é½Å»ó»ç¿¡¼´Â
ÀϺ» Á¦Á¶¼Ò·ÎºÎÅÍ °æÇÇ¿ë BCG ¹é½Å¿¡ ´ëÇÑ ¹æ»ç¼±·® Á¶»ç µ¥ÀÌÅ͸¦
üũÇÏ¿© ¹æ»ç¼±¿¡ ´ëÇÑ ¹®Á¦°¡ ¾øÀ½À» È®ÀÎÇϰí ÀÖ½À´Ï´Ù.
µû¶ó¼ ¾È½ÉÇÏ½Ã°í °æÇÇ¿ë BCG ¹é½ÅÀ» Á¢Á¾Çϼŵµ ±¦Âú½À´Ï´Ù.
¢ßÇѱ¹¹é½ÅÀº ¾ÕÀ¸·Îµµ öÀúÇÑ Ç°Áú°ü¸®¸¦ ÅëÇØ,
¼ÒÁßÇÑ ¿ì¸® ¾ÆÀ̵éÀÇ °Ç° ÁöÅ´À̷μ ÃÖ¼±À» ´ÙÇÒ °ÍÀ» ¾à¼Óµå¸³´Ï´Ù.
- Ref 1.°æÇÇ¿ë°ÇÁ¶ºñ¾¾Áö¹é½Å(ÀϺ»±ÕÁÖ) ǰ¸ñ Çã°¡Áõ.
|
|